Viridian Therapeutics (VRDN) Corporate presentation summary

Strategic vision and market focus

• Aspires to lead in autoimmune diseases, starting with thyroid eye disease (TED), aiming to address unmet needs and expand the treated patient population.

• Building a leadership position in TED to enable expansion into other autoimmune indications, supported by a robust pipeline and revenue-funded growth.

• TED market is valued at ~$2B annually, with low penetration and high demand for new entrants and subcutaneous options.

Product pipeline and clinical progress

• Portfolio includes veligrotug (IV), elegrobart (VRDN-003, SC), and a TSHR inhibitor, all targeting TED, with plans for FcRn inhibitor expansion into broader autoimmune diseases.

• Veligrotug met all primary and secondary endpoints in two phase 3 trials (THRIVE and THRIVE-2) for both active and chronic TED, showing rapid onset and robust, durable responses.

• Elegrobart, a subcutaneous anti-IGF-1R, is in phase 3 (REVEAL-1 and REVEAL-2), with topline data expected in Q1 and Q2 2026; designed for at-home autoinjector use every 4 or 8 weeks.

• TSHR inhibitor IND submission anticipated in Q4 2026, targeting TED and Graves’ disease.

Clinical data and safety

• Veligrotug demonstrated statistically significant improvements in proptosis, diplopia, and clinical activity score in both active and chronic TED, with rapid onset (as early as 3 weeks) and durable effects (70% maintained at 52 weeks).

• Generally well-tolerated safety profile for veligrotug, with low rates of hearing impairment and no treatment-related serious adverse events.

• Elegrobart phase 1 data showed extended half-life (40–50 days), sustained IGF-1 levels, and was well-tolerated with only mild adverse events.